Prostatic 25-hydroxyvitamin D-1α-hydroxylase and its implication in prostate cancer

被引:86
作者
Chen, TC
Wang, LL
Whitlatch, LW
Flanagan, JN
Holick, MF
机构
[1] Boston Univ, Sch Med, Med Ctr, Vitamin D Skin & Bone Res Lab, Boston, MA 02118 USA
[2] Boston Univ, Med Ctr, Dept Med, Boston, MA USA
[3] Boston Univ, Med Ctr, Div Endocrinol Diabet & Nutr, Boston, MA USA
关键词
vitamin D; promoter activity; cell cultures; luciferase; reporter gene;
D O I
10.1002/jcb.10342
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Evidence suggests that vitamin D may have a protective role for prostate cancer. 1alpha,25-Dihydroxyvitamin D [1alpha,25(OH)(2)D] inhibits growth and induces differentiation of prostate cells. 25-Hydroxyvitamin D-1alpha-hydroxylase [1alpha-OHase], the enzyme that is responsible for the synthesis of 1alpha,25(OH)(2)D, is expressed in cultured prostate cells. We observed a marked decrease in 1alpha-OHase activity in prostate cancer cells, suggesting some defect of the 1alpha-OHase in these cells. To investigate whether the defect was due to dysregulation of the enzyme at the promoter level, a series of deletion constructs of the promoter was synthesized and incorporated upstream into the luciferase reporter gene. Two regions were identified with high basal activity in transfected normal prostate cell line (PZHPV-7),-1100 bp (AN2), and -394 bp (AN5) upstream of ATG start site of the 1alpha-OHase gene. When the reporter gene with either AN2 or AN5 was transfected into prostate cancer cell lines, we observed a lower basal promoter activity in PC-3 cells and DU145 cells than that found in PZHPV-7 cells for both constructs, and a loss of promoter activity in LNCaP cells. Thus, the results suggest that the defect in enzyme activity may result from the decreased promoter activity in prostate cancer cells. J. Cell. Biochem. 88: 315-322,2003. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:315 / 322
页数:8
相关论文
共 29 条
  • [1] Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland)
    Ahonen, MH
    Tenkanen, L
    Teppo, L
    Hakama, M
    Tuohimaa, P
    [J]. CANCER CAUSES & CONTROL, 2000, 11 (09) : 847 - 852
  • [2] [Anonymous], P 1 INT C ENG COMP C
  • [3] NEONATAL HUMAN FORESKIN KERATINOCYTES PRODUCE 1,25-DIHYDROXYVITAMIN-D3
    BIKLE, DD
    NEMANIC, MK
    WHITNEY, JO
    ELIAS, PW
    [J]. BIOCHEMISTRY, 1986, 25 (07) : 1545 - 1548
  • [4] Parathyroid hormone activation of the 25-hydroxyvitamin D3-1α-hydroxylase gene promoter
    Brenza, HL
    Kimmel-Jehan, C
    Jehan, F
    Shinki, T
    Wakino, S
    Anazawa, H
    Suda, T
    DeLuca, HF
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (04) : 1387 - 1391
  • [5] Chen TC, 2000, CLIN CANCER RES, V6, P901
  • [6] CHARACTERIZATION OF PRIMARY-CELL CULTURES DERIVED FROM RAT RENAL PROXIMAL TUBULES
    CHEN, TC
    CURTHOYS, NP
    LAGENAUR, CF
    PUSCHETT, JB
    [J]. IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY, 1989, 25 (08): : 714 - 722
  • [7] CHEN TC, 1998, BONE S, V23, pS262
  • [8] DUSSO A, 1994, SEMIN NEPHROL, V14, P144
  • [9] Cloning of human 25-hydroxyvitamin D-1 alpha-hydroxylase and mutations causing vitamin D-dependent rickets type 1
    Fu, GK
    Lin, D
    Zhang, MYH
    Bikle, DD
    Shackleton, CHL
    Miller, WL
    Portale, AA
    [J]. MOLECULAR ENDOCRINOLOGY, 1997, 11 (13) : 1961 - 1970
  • [10] Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol)
    Gross, C
    Stamey, T
    Hancock, S
    Feldman, D
    [J]. JOURNAL OF UROLOGY, 1998, 159 (06) : 2035 - 2039